Clicky

Ocular Therapeutix, Inc.(OCUL)

Description: Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.


Keywords: Pain Inflammation Clinical Trial Hypertension Eye Glaucoma Sealant Platform Technology Cataracts Eye Diseases Allergology Incision Allergic Conjunctivitis Ocular Hypertension Cataract Surgery Incisions Treatment Of Glaucoma Cornea Bacterial Conjunctivitis Post Surgical Ocular Inflammation

Home Page: www.ocutx.com

OCUL Technical Analysis

24 Crosby Drive
Bedford, MA 01730
United States
Phone: 781 357 4000


Officers

Name Title
Mr. Antony Mattessich Pres, CEO & Director
Mr. Donald Notman Jr. Chief Financial Officer
Dr. Peter K. Jarrett Ph.D. Chief Scientific Officer
Mr. Philip C. Strassburger Gen. Counsel
Mr. William H. Ransone II VP of Global Sales & Marketing
Ms. Tracy Smith VP of HR
Mr. Scott Corning Sr. VP of Commercial
Mr. Christopher G. White Chief Bus. Officer
Dr. Rabia Gurses Ozden M.D. Chief Medical Officer
Dr. Karen-Leigh Edwards M.B.A., Ph.D. Sr. VP of Technical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.8976
Price-to-Sales TTM: 4.1736
IPO Date: 2014-07-25
Fiscal Year End: December
Full Time Employees: 228
Back to stocks